You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrazosin
Accession NumberDB00457  (APRD00020)
TypeSmall Molecule
GroupsApproved
DescriptionPrazosin is a selective α-1-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma.
Structure
Thumb
Synonyms
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
Prazosina
Prazosine
Prazosinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-prazosin-tab 1mgtablet1 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-prazosin-tab 2mgtablet2 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-prazosin-tab 5mgtablet5 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada
Minipresstablet1 mgoralErfa Canada 2012 Inc1983-12-31Not applicableCanada
Minipresscapsule1 mg/1oralPfizer Laboratories Div Pfizer Inc1994-05-10Not applicableUs
Minipresstablet2 mgoralErfa Canada 2012 Inc1983-12-31Not applicableCanada
Minipresscapsule2 mg/1oralPfizer Laboratories Div Pfizer Inc1994-05-10Not applicableUs
Minipresscapsule5 mg/1oralPfizer Laboratories Div Pfizer Inc1994-05-10Not applicableUs
Minipresstablet5 mgoralErfa Canada 2012 Inc1983-12-31Not applicableCanada
Nu-prazo Tab 1mgtablet1 mgoralNu Pharm Inc1992-12-312012-09-04Canada
Nu-prazo Tab 2mgtablet2 mgoralNu Pharm Inc1992-12-312012-09-04Canada
Nu-prazo Tab 5mgtablet5 mgoralNu Pharm Inc1992-12-312012-09-04Canada
Prazosin-1 Tab 1mgtablet1 mgoralPro Doc Limitee1991-12-312009-07-23Canada
Prazosin-2 Tab 2mgtablet2 mgoralPro Doc Limitee1991-12-312009-07-23Canada
Prazosin-5 Tabtablet5 mgoralPro Doc Limitee1991-12-312009-07-23Canada
Rho-prazosin - Tab 1mgtablet1 mgoralRhodiapharm Inc1995-12-311998-08-05Canada
Rho-prazosin - Tab 5mgtablet5 mgoralRhodiapharm Inc1995-12-311998-08-05Canada
Rho-prazosin-tab 2mgtablet2 mgoralRhodiapharm Inc1995-12-311998-08-05Canada
Teva-prazosintablet2 mgoralTeva Canada Limited1992-12-31Not applicableCanada
Teva-prazosintablet5 mgoralTeva Canada Limited1992-12-31Not applicableCanada
Teva-prazosintablet1 mgoralTeva Canada Limited1992-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-prazo Tab 1mgtablet1 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-prazo Tab 2mgtablet2 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-prazo Tab 5mgtablet5 mgoralApotex Inc1990-12-31Not applicableCanada
Prazosin Hydrochloridecapsule2 mg/1oralAidarex Pharmaceuticals LLC2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralLake Erie Medical DBA Quality Care Products LLC1989-02-28Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralTeva Pharmaceuticals USA Inc2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralMylan Institutional Inc.1998-10-05Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralAphena Pharma Solutions Tennessee, Llc2013-05-17Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralREMEDYREPACK INC.2013-05-28Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralCardinal Health1998-10-05Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralMylan Pharmaceuticals Inc.1989-02-28Not applicableUs
Prazosin Hydrochloridecapsule5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-02-10Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralbryant ranch prepack2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralTeva Pharmaceuticals USA Inc2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralMylan Institutional Inc.1998-10-06Not applicableUs
Prazosin Hydrochloridecapsule5 mg/1oralREMEDYREPACK INC.2016-01-22Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralREMEDYREPACK INC.2010-10-11Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralCarilion Materials Management2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule5 mg/1oralMylan Pharmaceuticals Inc.1989-02-28Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralPd Rx Pharmaceuticals, Inc.2010-02-10Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralTYA Pharmaceuticals2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule5 mg/1oralTeva Pharmaceuticals USA Inc2007-01-18Not applicableUs
Prazosin Hydrochloridecapsule5 mg/1oralMylan Institutional Inc.1998-10-06Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralA S Medication Solutions2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule5 mg/1oralREMEDYREPACK INC.2011-04-21Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralAidarex Pharmaceuticals LLC2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralPhysicians Total Care, Inc.2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralAphena Pharma Solutions Tennessee, Inc.2009-12-21Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Prazosin Hydrochloridecapsule1 mg/1oralMylan Pharmaceuticals Inc.1989-02-28Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralREMEDYREPACK INC.2013-05-28Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralA S Medication Solutions2007-02-22Not applicableUs
Prazosin Hydrochloridecapsule2 mg/1oralREMEDYREPACK INC.2011-11-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HypovaseNot Available
Minipress XlPfizer
PressinNot Available
VasoflexNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Prazosin Hydrochloride
19237-84-4
Thumb
  • InChI Key: WFXFYZULCQKPIP-UHFFFAOYSA-N
  • Monoisotopic Mass: 419.136031924
  • Average Mass: 419.862
DBSALT000329
Categories
UNIIXM03YJ541D
CAS number19216-56-9
WeightAverage: 383.4011
Monoisotopic: 383.159354185
Chemical FormulaC19H21N5O4
InChI KeyInChIKey=IENZQIKPVFGBNW-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
IUPAC Name
2-[4-(furan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Quinazolinamine
  • Quinazoline
  • Dialkylarylamine
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Primary aromatic amine
  • Heteroaromatic compound
  • Furan
  • Tertiary amine
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma.
PharmacodynamicsPrazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Prazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Prazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Prazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Prazosin results from a decrease in systemic vascular resistance and the parent compound Prazosin is primarily responsible for the antihypertensive activity.
Mechanism of actionPrazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Related Articles
AbsorptionWell-absorbed from gastrointestinal tract; bioavailability is variable (50 to 85%).
Volume of distributionNot Available
Protein binding97%
Metabolism

Primarily hepatic. Several metabolites have been identified in humans and animals (6- O -demethyl, 7- O -demethyl, 2-[1-piperazinyl]-4-amino-6, 7-dimethoxyquinazoline, 2,4-diamino-6,7-dimethoxyquinazoline).

SubstrateEnzymesProduct
Prazosin
Not Available
2,4-diamino-6,7-dimethoxyquinazolineDetails
Prazosin
Not Available
6-O-demethyl,7-O-demethyl,2-[1-piperazinyl]-4-amino-6,7-dimethoxyquinazolineDetails
Route of eliminationAnimal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man.
Half life2-3 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9479
Caco-2 permeable+0.8298
P-glycoprotein substrateSubstrate0.7193
P-glycoprotein inhibitor INon-inhibitor0.5747
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.6405
CYP450 2C9 substrateNon-substrate0.8773
CYP450 2D6 substrateNon-substrate0.7641
CYP450 3A4 substrateSubstrate0.7577
CYP450 1A2 substrateNon-inhibitor0.8434
CYP450 2C9 inhibitorNon-inhibitor0.9278
CYP450 2D6 inhibitorNon-inhibitor0.9685
CYP450 2C19 inhibitorNon-inhibitor0.9169
CYP450 3A4 inhibitorNon-inhibitor0.7608
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8049
Ames testNon AMES toxic0.5581
CarcinogenicityNon-carcinogens0.9199
BiodegradationNot ready biodegradable0.9818
Rat acute toxicity2.3304 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8352
hERG inhibition (predictor II)Inhibitor0.8489
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer laboratories div pfizer inc
  • American therapeutics inc
  • Clonmel healthcare ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Watson laboratories inc
  • Pfizer inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg
Tabletoral2 mg
Tabletoral5 mg
Capsuleoral1 mg/1
Capsuleoral2 mg/1
Capsuleoral5 mg/1
Prices
Unit descriptionCostUnit
Minipress 5 mg capsule1.97USD capsule
Minipress 2 mg capsule1.14USD capsule
Prazosin HCl 5 mg capsule0.98USD capsule
Prazosin 5 mg capsule0.94USD capsule
Minipress 1 mg capsule0.83USD capsule
Prazosin HCl 2 mg capsule0.57USD capsule
Prazosin 2 mg capsule0.55USD capsule
Prazosin HCl 1 mg capsule0.41USD capsule
Prazosin 1 mg capsule0.4USD capsule
Apo-Prazo 5 mg Tablet0.4USD tablet
Novo-Prazin 5 mg Tablet0.4USD tablet
Nu-Prazo 5 mg Tablet0.4USD tablet
Vasoflex hd caplet0.38USD caplet
Vasoflex forte capsule0.29USD capsule
Apo-Prazo 2 mg Tablet0.29USD tablet
Novo-Prazin 2 mg Tablet0.29USD tablet
Nu-Prazo 2 mg Tablet0.29USD tablet
Apo-Prazo 1 mg Tablet0.22USD tablet
Novo-Prazin 1 mg Tablet0.22USD tablet
Nu-Prazo 1 mg Tablet0.22USD tablet
Vasoflex tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point279 °CPhysProp
water solubility0.5 mg/mL (HCl salt)Sigma Aldrich
logP1.3Not Available
Caco2 permeability-4.36ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.693 mg/mLALOGPS
logP1.93ALOGPS
logP1.65ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area106.95 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity104.5 m3·mol-1ChemAxon
Polarizability40.49 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Stig O. E. Lindholm, “A process for the preparation of anhydrous, stable, crystalline delta-form of prazosin hydrochloride.” U.S. Patent US4873330, issued 0000.

US4873330
General References
  1. Bawaskar HS, Bawaskar PH: Utility of scorpion antivenin vs prazosin in the management of severe Mesobuthus tamulus (Indian red scorpion) envenoming at rural setting. J Assoc Physicians India. 2007 Jan;55:14-21. [PubMed:17444339 ]
  2. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]
  3. Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I: Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):49-56. Epub 2003 Jun 25. [PubMed:12827214 ]
  4. Link [Link]
External Links
ATC CodesC02CA01C02LE01
AHFS Codes
  • 24:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57.2 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Prazosin.
AcebutololPrazosin may increase the hypotensive activities of Acebutolol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Prazosin.
AcetazolamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Acetazolamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Prazosin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Prazosin.
AlbendazoleThe serum concentration of Prazosin can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.
AldosteroneThe serum concentration of Prazosin can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Prazosin.
AlectinibThe serum concentration of Prazosin can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Prazosin can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the antihypertensive activities of Prazosin.
AliskirenPrazosin may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Prazosin.
AlprenololPrazosin may increase the hypotensive activities of Alprenolol.
AmantadineThe serum concentration of Prazosin can be increased when it is combined with Amantadine.
AmbrisentanPrazosin may increase the hypotensive activities of Ambrisentan.
AmifostinePrazosin may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Prazosin is combined with Amiloride.
Aminohippuric acidThe serum concentration of Prazosin can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Prazosin can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Prazosin.
AmlodipineAmlodipine may increase the hypotensive activities of Prazosin.
AmobarbitalAmobarbital may increase the hypotensive activities of Prazosin.
AmprenavirThe serum concentration of Prazosin can be decreased when it is combined with Amprenavir.
AmrinonePrazosin may increase the hypotensive activities of Amrinone.
AmsacrineThe serum concentration of Prazosin can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Prazosin is combined with Amyl Nitrite.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Prazosin.
ApraclonidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Apraclonidine.
AripiprazoleAripiprazole may increase the hypotensive activities of Prazosin.
ArotinololArotinolol may increase the orthostatic hypotensive activities of Prazosin.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Prazosin.
AstemizoleThe serum concentration of Prazosin can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Prazosin.
AtenololAtenolol may increase the hypotensive activities of Prazosin.
AtorvastatinThe serum concentration of Prazosin can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Prazosin.
AzelastineThe serum concentration of Prazosin can be increased when it is combined with Azelastine.
AzelnidipinePrazosin may increase the hypotensive activities of Azelnidipine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Prazosin is combined with Azilsartan medoxomil.
AzimilidePrazosin may increase the hypotensive activities of Azimilide.
AzithromycinThe serum concentration of Prazosin can be increased when it is combined with Azithromycin.
BarbitalBarbital may increase the hypotensive activities of Prazosin.
BarnidipinePrazosin may increase the hypotensive activities of Barnidipine.
BefunololBefunolol may increase the orthostatic hypotensive activities of Prazosin.
BenazeprilPrazosin may increase the hypotensive activities of Benazepril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Prazosin.
BenidipinePrazosin may increase the hypotensive activities of Benidipine.
BenmoxinBenmoxin may increase the hypotensive activities of Prazosin.
BenzocaineThe serum concentration of Prazosin can be increased when it is combined with Benzocaine.
BepridilPrazosin may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Prazosin.
BetaxololBetaxolol may increase the hypotensive activities of Prazosin.
BethanidineBethanidine may increase the hypotensive activities of Prazosin.
BevantololBevantolol may increase the orthostatic hypotensive activities of Prazosin.
BimatoprostPrazosin may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Prazosin can be increased when it is combined with Biperiden.
BisoprololPrazosin may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Prazosin.
BopindololBopindolol may increase the orthostatic hypotensive activities of Prazosin.
BosentanPrazosin may increase the hypotensive activities of Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Prazosin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prazosin.
BretyliumPrazosin may increase the hypotensive activities of Bretylium.
BrimonidinePrazosin may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Prazosin.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Prazosin.
BufuralolBufuralol may increase the orthostatic hypotensive activities of Prazosin.
BumetanideThe risk or severity of adverse effects can be increased when Prazosin is combined with Bumetanide.
BupranololPrazosin may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Prazosin can be increased when it is combined with Buprenorphine.
BupropionThe serum concentration of Prazosin can be increased when it is combined with Bupropion.
BuspironeThe serum concentration of Prazosin can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Prazosin.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Prazosin.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Prazosin.
CanagliflozinThe risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.
CandesartanPrazosin may increase the hypotensive activities of Candesartan.
CandoxatrilPrazosin may increase the hypotensive activities of Candoxatril.
CaptoprilPrazosin may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Prazosin can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Prazosin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Prazosin.
CaroxazoneCaroxazone may increase the hypotensive activities of Prazosin.
CarteololPrazosin may increase the hypotensive activities of Carteolol.
CarvedilolPrazosin may increase the antihypertensive activities of Carvedilol.
CaspofunginThe serum concentration of Prazosin can be increased when it is combined with Caspofungin.
CeliprololPrazosin may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Prazosin.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Prazosin.
ChloroquineThe serum concentration of Prazosin can be increased when it is combined with Chloroquine.
ChlorothiazidePrazosin may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Prazosin.
ChlorpropamideThe serum concentration of Prazosin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Prazosin can be increased when it is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Prazosin.
CholesterolThe serum concentration of Prazosin can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Prazosin can be decreased when it is combined with Cholic Acid.
CilazaprilPrazosin may increase the hypotensive activities of Cilazapril.
CilnidipinePrazosin may increase the hypotensive activities of Cilnidipine.
CimetidineThe serum concentration of Prazosin can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Prazosin.
CinnarizinePrazosin may increase the hypotensive activities of Cinnarizine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Prazosin.
CirazolinePrazosin may decrease the vasoconstricting activities of Cirazoline.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Prazosin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Prazosin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Prazosin.
ClevidipinePrazosin may increase the hypotensive activities of Clevidipine.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Prazosin.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Prazosin.
ClofazimineThe serum concentration of Prazosin can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Prazosin.
ClomipramineThe serum concentration of Prazosin can be increased when it is combined with Clomipramine.
ClonidinePrazosin may increase the hypotensive activities of Clonidine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Prazosin.
ClotrimazoleThe serum concentration of Prazosin can be decreased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Prazosin.
CobicistatThe serum concentration of Prazosin can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Prazosin.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Prazosin.
ColforsinThe serum concentration of Prazosin can be increased when it is combined with Colforsin.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Prazosin.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Prazosin.
CryptenaminePrazosin may increase the hypotensive activities of Cryptenamine.
CyclophosphamideThe serum concentration of Prazosin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Prazosin can be decreased when it is combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Prazosin.
CyclothiazidePrazosin may increase the hypotensive activities of Cyclothiazide.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Prazosin.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Prazosin.
DaclatasvirThe serum concentration of Prazosin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Prazosin.
DapagliflozinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Prazosin.
DarodipinePrazosin may increase the hypotensive activities of Darodipine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Prazosin.
DaunorubicinThe serum concentration of Prazosin can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Prazosin.
DebrisoquinPrazosin may increase the hypotensive activities of Debrisoquin.
DeserpidinePrazosin may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Prazosin can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Prazosin can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Prazosin can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Prazosin.
DexmedetomidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Dexmedetomidine.
DextromethorphanThe serum concentration of Prazosin can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Prazosin.
DiazoxideDiazoxide may increase the hypotensive activities of Prazosin.
DiclofenacThe serum concentration of Prazosin can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Prazosin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Prazosin.
DigoxinThe serum concentration of Prazosin can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Prazosin.
DihydroergotamineThe serum concentration of Prazosin can be increased when it is combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Prazosin.
DiltiazemDiltiazem may increase the hypotensive activities of Prazosin.
DinutuximabThe risk or severity of adverse effects can be increased when Prazosin is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Prazosin is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Prazosin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Prazosin.
DorzolamidePrazosin may increase the hypotensive activities of Dorzolamide.
DotarizinePrazosin may increase the hypotensive activities of Dotarizine.
DoxazosinPrazosin may increase the antihypertensive activities of Doxazosin.
DoxepinThe serum concentration of Prazosin can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Prazosin can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Prazosin.
DronabinolThe serum concentration of Prazosin can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Prazosin can be increased when it is combined with Dronedarone.
DuloxetinePrazosin may increase the orthostatic hypotensive activities of Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Prazosin.
EfonidipinePrazosin may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Prazosin can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Prazosin.
EltrombopagThe serum concentration of Prazosin can be increased when it is combined with Eltrombopag.
EmpagliflozinThe risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.
EnalaprilPrazosin may increase the hypotensive activities of Enalapril.
EnalaprilatPrazosin may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Prazosin can be increased when it is combined with Enzalutamide.
EperisonePrazosin may increase the hypotensive activities of Eperisone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Prazosin.
EplerenoneThe risk or severity of adverse effects can be increased when Prazosin is combined with Eplerenone.
EpoprostenolPrazosin may increase the hypotensive activities of Epoprostenol.
EprosartanPrazosin may increase the hypotensive activities of Eprosartan.
ErgonovineThe serum concentration of Prazosin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Prazosin can be increased when it is combined with Ergotamine.
ErgotaminePrazosin may decrease the vasoconstricting activities of Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Prazosin.
ErythromycinThe serum concentration of Prazosin can be decreased when it is combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Prazosin.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Prazosin.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Prazosin.
EstramustineThe serum concentration of Prazosin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Prazosin can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Prazosin.
EstroneThe serum concentration of Prazosin can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Prazosin.
Etacrynic acidThe risk or severity of adverse effects can be increased when Prazosin is combined with Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Prazosin.
EtoposideThe serum concentration of Prazosin can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Prazosin can be increased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Prazosin.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Prazosin.
FelodipinePrazosin may increase the hypotensive activities of Felodipine.
FendilinePrazosin may increase the hypotensive activities of Fendiline.
FenoldopamPrazosin may increase the hypotensive activities of Fenoldopam.
FentanylThe serum concentration of Prazosin can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Prazosin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Prazosin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Prazosin.
FluconazoleThe serum concentration of Prazosin can be increased when it is combined with Fluconazole.
FlunarizinePrazosin may increase the hypotensive activities of Flunarizine.
FluoxetineThe serum concentration of Prazosin can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Prazosin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Prazosin can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Prazosin can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Prazosin.
FluvoxamineThe serum concentration of Prazosin can be increased when it is combined with Fluvoxamine.
FosinoprilPrazosin may increase the hypotensive activities of Fosinopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Prazosin.
FurosemideThe risk or severity of adverse effects can be increased when Prazosin is combined with Furosemide.
GabapentinPrazosin may increase the hypotensive activities of Gabapentin.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Prazosin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Prazosin.
GenisteinThe serum concentration of Prazosin can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Prazosin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Prazosin can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Prazosin can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Prazosin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Prazosin.
GuanabenzPrazosin may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Prazosin.
GuanethidinePrazosin may increase the hypotensive activities of Guanethidine.
GuanfacinePrazosin may increase the hypotensive activities of Guanfacine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Prazosin.
HexamethoniumPrazosin may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Prazosin.
HydracarbazineHydracarbazine may increase the hypotensive activities of Prazosin.
HydralazinePrazosin may increase the hypotensive activities of Hydralazine.
HydrochlorothiazidePrazosin may increase the hypotensive activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Prazosin.
HydroflumethiazidePrazosin may increase the hypotensive activities of Hydroflumethiazide.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Prazosin.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Prazosin.
IloprostIloprost may increase the hypotensive activities of Prazosin.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Prazosin.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Prazosin.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Prazosin.
IndapamidePrazosin may increase the hypotensive activities of Indapamide.
IndenololPrazosin may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Prazosin can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Prazosin.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Prazosin.
IndoraminPrazosin may increase the antihypertensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Prazosin.
IproniazidIproniazid may increase the hypotensive activities of Prazosin.
IrbesartanPrazosin may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Prazosin.
IsavuconazoniumThe serum concentration of Prazosin can be increased when it is combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Prazosin.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Prazosin is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Prazosin.
ItraconazoleThe serum concentration of Prazosin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Prazosin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Prazosin.
KetamineThe serum concentration of Prazosin can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Prazosin.
KetoconazoleThe serum concentration of Prazosin can be increased when it is combined with Ketoconazole.
LabetalolPrazosin may increase the antihypertensive activities of Labetalol.
LacidipinePrazosin may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Prazosin.
LamotriginePrazosin may increase the hypotensive activities of Lamotrigine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Prazosin.
LapatinibThe serum concentration of Prazosin can be increased when it is combined with Lapatinib.
LatanoprostPrazosin may increase the hypotensive activities of Latanoprost.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Prazosin.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Prazosin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Prazosin.
LercanidipinePrazosin may increase the hypotensive activities of Lercanidipine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Prazosin.
LevobunololThe risk or severity of adverse effects can be increased when Prazosin is combined with Levobunolol.
LevodopaPrazosin may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Prazosin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Prazosin.
LevothyroxineThe serum concentration of Prazosin can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Prazosin can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Prazosin.
LiothyronineThe serum concentration of Prazosin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Prazosin can be decreased when it is combined with Liotrix.
LisinoprilPrazosin may increase the hypotensive activities of Lisinopril.
LofexidinePrazosin may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Prazosin can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Prazosin.
LopinavirThe serum concentration of Prazosin can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Prazosin can be increased when it is combined with Loratadine.
LosartanPrazosin may increase the hypotensive activities of Losartan.
LovastatinThe serum concentration of Prazosin can be increased when it is combined with Lovastatin.
LumacaftorThe serum concentration of Prazosin can be decreased when it is combined with Lumacaftor.
MacitentanPrazosin may increase the hypotensive activities of Macitentan.
Magnesium SulfatePrazosin may increase the hypotensive activities of Magnesium Sulfate.
ManidipinePrazosin may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Prazosin is combined with Mannitol.
MaprotilineThe serum concentration of Prazosin can be increased when it is combined with Maprotiline.
MebanazineMebanazine may increase the hypotensive activities of Prazosin.
MebendazoleThe serum concentration of Prazosin can be increased when it is combined with Mebendazole.
MecamylaminePrazosin may increase the hypotensive activities of Mecamylamine.
MefloquineThe serum concentration of Prazosin can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Prazosin can be increased when it is combined with Megestrol acetate.
MephenterminePrazosin may decrease the vasoconstricting activities of Mephentermine.
MeprobamateThe serum concentration of Prazosin can be increased when it is combined with Meprobamate.
MetaraminolPrazosin may decrease the vasoconstricting activities of Metaraminol.
MethadoneThe serum concentration of Prazosin can be increased when it is combined with Methadone.
MethazolamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Prazosin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Prazosin.
MethoxaminePrazosin may decrease the vasoconstricting activities of Methoxamine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Prazosin.
MethyldopaPrazosin may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Prazosin.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Prazosin.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Prazosin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Prazosin.
MetipranololPrazosin may increase the hypotensive activities of Metipranolol.
MetolazonePrazosin may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Prazosin.
MibefradilPrazosin may increase the hypotensive activities of Mibefradil.
MiconazoleThe serum concentration of Prazosin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Prazosin can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Prazosin.
MidodrinePrazosin may decrease the vasoconstricting activities of Midodrine.
MifepristoneThe serum concentration of Prazosin can be decreased when it is combined with Mifepristone.
MinaprineMinaprine may increase the hypotensive activities of Prazosin.
MinoxidilMinoxidil may increase the hypotensive activities of Prazosin.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Prazosin.
MitomycinThe serum concentration of Prazosin can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Prazosin can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Prazosin.
MoclobemideMoclobemide may increase the hypotensive activities of Prazosin.
MoexiprilPrazosin may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Prazosin.
MorphineThe serum concentration of Morphine can be increased when it is combined with Prazosin.
MoxonidinePrazosin may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Prazosin.
NadololPrazosin may increase the hypotensive activities of Nadolol.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Prazosin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Prazosin.
NaltrexoneThe serum concentration of Prazosin can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Prazosin can be increased when it is combined with Naringenin.
NebivololPrazosin may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Prazosin can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Prazosin can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Prazosin.
NeostigmineThe serum concentration of Prazosin can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Prazosin is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Prazosin.
NicardipinePrazosin may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Prazosin.
NifedipinePrazosin may increase the hypotensive activities of Nifedipine.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Prazosin.
NiguldipinePrazosin may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Prazosin.
NiludipinePrazosin may increase the hypotensive activities of Niludipine.
NilvadipinePrazosin may increase the hypotensive activities of Nilvadipine.
NimesulidePrazosin may increase the hypotensive activities of Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Prazosin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Prazosin.
NisoldipineNisoldipine may increase the hypotensive activities of Prazosin.
NitrazepamThe serum concentration of Prazosin can be increased when it is combined with Nitrazepam.
NitrendipinePrazosin may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Prazosin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Prazosin.
NorethisteroneThe serum concentration of Prazosin can be decreased when it is combined with Norethisterone.
ObinutuzumabPrazosin may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Prazosin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Prazosin.
OlmesartanOlmesartan may increase the hypotensive activities of Prazosin.
OmapatrilatPrazosin may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Prazosin.
OmeprazoleThe serum concentration of Prazosin can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Prazosin.
OxprenololPrazosin may increase the hypotensive activities of Oxprenolol.
P-NitrophenolThe serum concentration of Prazosin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Prazosin can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Prazosin can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Prazosin.
PantoprazoleThe serum concentration of Prazosin can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Prazosin is combined with Papaverine.
PargylinePrazosin may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Prazosin can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Prazosin.
PenbutololPrazosin may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Prazosin.
PentoliniumPrazosin may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Prazosin.
PerhexilinePrazosin may increase the hypotensive activities of Perhexiline.
PerindoprilPrazosin may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Prazosin.
PheniprazinePheniprazine may increase the hypotensive activities of Prazosin.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Prazosin.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Prazosin.
PhenoxybenzaminePrazosin may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Prazosin.
PhentolaminePrazosin may increase the hypotensive activities of Phentolamine.
PhenylephrinePrazosin may decrease the vasoconstricting activities of Phenylephrine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Prazosin.
PimozideThe serum concentration of Prazosin can be increased when it is combined with Pimozide.
PinacidilPrazosin may increase the hypotensive activities of Pinacidil.
PinaveriumPrazosin may increase the hypotensive activities of Pinaverium.
PindololPrazosin may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Prazosin.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Prazosin.
PivhydrazinePivhydrazine may increase the hypotensive activities of Prazosin.
Platelet Activating FactorThe serum concentration of Prazosin can be decreased when it is combined with Platelet Activating Factor.
PolythiazidePrazosin may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Prazosin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Prazosin.
PosaconazoleThe serum concentration of Prazosin can be increased when it is combined with Posaconazole.
PractololPractolol may increase the orthostatic hypotensive activities of Prazosin.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Prazosin.
PregabalinPrazosin may increase the hypotensive activities of Pregabalin.
PrenylaminePrazosin may increase the hypotensive activities of Prenylamine.
PrimidonePrimidone may increase the hypotensive activities of Prazosin.
ProbenecidThe serum concentration of Prazosin can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Prazosin can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Prazosin.
PromethazineThe serum concentration of Prazosin can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Prazosin can be increased when it is combined with Propafenone.
PropranololPrazosin may increase the hypotensive activities of Propranolol.
ProtriptylineThe serum concentration of Prazosin can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Prazosin.
QuercetinThe serum concentration of Prazosin can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Prazosin is combined with Quetiapine.
QuinacrineThe serum concentration of Prazosin can be increased when it is combined with Quinacrine.
QuinaprilPrazosin may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Prazosin can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Prazosin.
QuinineThe serum concentration of Quinine can be increased when it is combined with Prazosin.
RamiprilRamipril may increase the hypotensive activities of Prazosin.
RanitidineThe serum concentration of Prazosin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Prazosin.
RasagilineRasagiline may increase the hypotensive activities of Prazosin.
ReboxetineThe serum concentration of Prazosin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Prazosin can be increased when it is combined with Regorafenib.
RemikirenRemikiren may increase the hypotensive activities of Prazosin.
RescinnaminePrazosin may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Prazosin.
RifampicinThe serum concentration of Prazosin can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Prazosin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Prazosin.
RilpivirineThe serum concentration of Prazosin can be increased when it is combined with Rilpivirine.
RiociguatPrazosin may increase the hypotensive activities of Riociguat.
RisedronatePrazosin may increase the hypotensive activities of Risedronate.
RisperidonePrazosin may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Prazosin can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Prazosin.
RituximabPrazosin may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Prazosin.
RolapitantThe serum concentration of Prazosin can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Prazosin.
SafrazineSafrazine may increase the hypotensive activities of Prazosin.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Prazosin.
SaprisartanPrazosin may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Prazosin can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Prazosin.
ScopolamineThe serum concentration of Prazosin can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Prazosin.
SelegilineSelegiline may increase the hypotensive activities of Prazosin.
SelexipagPrazosin may increase the hypotensive activities of Selexipag.
SertralineThe serum concentration of Prazosin can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Prazosin.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Prazosin.
SilodosinSilodosin may increase the antihypertensive activities of Prazosin.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Prazosin.
SimvastatinThe serum concentration of Prazosin can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Prazosin can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Prazosin.
SitaxentanPrazosin may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Prazosin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Prazosin.
SotalolThe risk or severity of adverse effects can be increased when Prazosin is combined with Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Prazosin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Prazosin.
SpiraprilPrazosin may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Prazosin.
St. John's WortThe serum concentration of Prazosin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Prazosin can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Prazosin can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Prazosin can be increased when it is combined with Sulfinpyrazone.
SumatriptanThe serum concentration of Prazosin can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Prazosin can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Prazosin can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Prazosin can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Prazosin.
TadalafilTadalafil may increase the antihypertensive activities of Prazosin.
TamoxifenThe serum concentration of Prazosin can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Prazosin.
TamsulosinPrazosin may increase the antihypertensive activities of Tamsulosin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Prazosin.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Prazosin.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Prazosin.
TelmisartanPrazosin may increase the hypotensive activities of Telmisartan.
TemocaprilPrazosin may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Prazosin.
TerazosinPrazosin may increase the antihypertensive activities of Terazosin.
TerfenadineThe serum concentration of Prazosin can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Prazosin can be increased when it is combined with Teriflunomide.
TerlipressinPrazosin may increase the hypotensive activities of Terlipressin.
TesmilifeneThe serum concentration of Prazosin can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Prazosin can be increased when it is combined with Testosterone.
ThiamylalThiamylal may increase the hypotensive activities of Prazosin.
ThiopentalThiopental may increase the hypotensive activities of Prazosin.
TibolonePrazosin may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Prazosin.
TicrynafenPrazosin may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Prazosin.
TizanidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Tizanidine.
TolazolinePrazosin may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidPrazosin may increase the hypotensive activities of Tolfenamic Acid.
ToloxatoneToloxatone may increase the hypotensive activities of Prazosin.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Prazosin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Prazosin.
TorasemideTorasemide may increase the hypotensive activities of Prazosin.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Prazosin.
TrandolaprilPrazosin may increase the hypotensive activities of Trandolapril.
TranilastPrazosin may increase the hypotensive activities of Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Prazosin.
TranylcypromineTranylcypromine may increase the hypotensive activities of Prazosin.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Prazosin.
TravoprostTravoprost may increase the hypotensive activities of Prazosin.
TrazodoneThe serum concentration of Prazosin can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Prazosin.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Prazosin.
TrichlormethiazidePrazosin may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Prazosin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Prazosin can be increased when it is combined with Triflupromazine.
TrimazosinPrazosin may increase the antihypertensive activities of Trimazosin.
TrimethaphanPrazosin may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe serum concentration of Prazosin can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Prazosin can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Prazosin can be increased when it is combined with Troleandomycin.
UdenafilUdenafil may increase the antihypertensive activities of Prazosin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Prazosin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Prazosin.
UnoprostonePrazosin may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Prazosin.
VardenafilVardenafil may increase the antihypertensive activities of Prazosin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Prazosin.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Prazosin.
VerapamilPrazosin may increase the hypotensive activities of Verapamil.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Prazosin.
VinblastineThe serum concentration of Prazosin can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Prazosin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Prazosin.
VincristineThe serum concentration of Prazosin can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Prazosin can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Prazosin.
XylometazolinePrazosin may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Prazosin.
ZiconotidePrazosin may increase the hypotensive activities of Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Prazosin.
ZimelidineThe serum concentration of Prazosin can be increased when it is combined with Zimelidine.
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Chang HK, Hsu FL, Liu IM, Cheng JT: Stimulatory effect of cinnamic acid analogues on alpha1A-adrenoceptors in-vitro. J Pharm Pharmacol. 2003 Jun;55(6):833-7. [PubMed:12841945 ]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  3. Morris DP, Price RR, Smith MP, Lei B, Schwinn DA: Cellular trafficking of human alpha1a-adrenergic receptors is continuous and primarily agonist-independent. Mol Pharmacol. 2004 Oct;66(4):843-54. Epub 2004 Jul 16. [PubMed:15258254 ]
  4. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
  5. Suzuki Y, Kanada A, Okaya Y, Aisaka K: Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. Eur J Pharmacol. 2000 Apr 7;394(1):123-30. [PubMed:10771044 ]
  6. Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y: Expressions and mechanical functions of alpha1-adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5. Epub 2007 Jul 6. [PubMed:17658513 ]
  7. Zacharia J, Hillier C, MacDonald A: Alpha1-adrenoceptor subtypes involved in vasoconstrictor responses to exogenous and neurally released noradrenaline in rat femoral resistance arteries. Br J Pharmacol. 2004 Mar;141(6):915-24. Epub 2004 Feb 23. [PubMed:14980979 ]
  8. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Al-Damluji S, Shen WB, White S, Barnard EA: alpha(1B) adrenergic receptors in gonadotrophin-releasing hormone neurones: relation to Transport-P. Br J Pharmacol. 2001 Jan;132(1):336-44. [PubMed:11156594 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  4. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758 ]
  5. Sharpe IA, Thomas L, Loughnan M, Motin L, Palant E, Croker DE, Alewood D, Chen S, Graham RM, Alewood PF, Adams DJ, Lewis RJ: Allosteric alpha 1-adrenoreceptor antagonism by the conopeptide rho-TIA. J Biol Chem. 2003 Sep 5;278(36):34451-7. Epub 2003 Jun 24. [PubMed:12824165 ]
  6. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
  7. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Nagaoka Y, Ahmed M, Hossain M, Bhuiyan MA, Ishiguro M, Nakamura T, Watanabe M, Nagatomo T: Amino acids of the human alpha1d-adrenergic receptor involved in antagonist binding. J Pharmacol Sci. 2008 Jan;106(1):114-20. Epub 2008 Jan 11. [PubMed:18187928 ]
  2. Yamamoto Y, Koike K: alpha(1)-Adrenoceptor subtypes in the mouse mesenteric artery and abdominal aorta. Br J Pharmacol. 2001 Nov;134(5):1045-54. [PubMed:11682453 ]
  3. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH6
Uniprot ID:
Q9H252
Molecular Weight:
109923.705 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH7
Uniprot ID:
Q9NS40
Molecular Weight:
134998.525 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Pan G, Winter TN, Roberts JC, Fairbanks CA, Elmquist WF: Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells. Mol Pharm. 2010 Feb 1;7(1):138-45. doi: 10.1021/mp900177r. [PubMed:19886673 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  3. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]
  4. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  5. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV: Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9. [PubMed:9380680 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  2. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23